Multicentre, open label, uncontrolled, pilot, phase II study of oral ITF2357 in subjects with acute myeloid leukemia refractory/resistant and/or not suitable for any alternative therapy.

Trial Profile

Multicentre, open label, uncontrolled, pilot, phase II study of oral ITF2357 in subjects with acute myeloid leukemia refractory/resistant and/or not suitable for any alternative therapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 May 2011

At a glance

  • Drugs Givinostat (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors Italfarmaco
  • Most Recent Events

    • 25 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top